Navigation Links
Peptimmune Presentations at Upcoming Events
Date:10/28/2008

CAMBRIDGE, Mass., Oct. 28 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced today that President & CEO Thomas P. Mathers will provide an update on the Company's current phase Ib clinical trial for PI-2301 in multiple sclerosis patients at the three upcoming events:

1. BIO Investor Forum 2008. The presentation will take place on Wednesday,

October 29th, at 3:15 p.m. in the Pacific Room at the Palace Hotel in

San Francisco.

2. Oppenheimer 19th Annual Healthcare Conference. The presentation will

take place on Tuesday, November 4th, at 10:40 a.m. in the Louis XVI

Room at the Waldorf-Astoria Hotel in New York City.

3. Rodman & Renshaw 10th Annual Healthcare Conference. The presentation

will take place on Wednesday, November 12th, at 2:25 p.m. in the Adams

Room at the New York Palace Hotel in New York City.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has put in place high-quality synthesis and analytical methods that provide a superior level of batch-to-batch reproducibility in the manufacturing of PI-2301.

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve-insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peptimmune Announces First Close of Series D Private Financing
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
4. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
5. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
6. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
7. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
8. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 Despite the volatility that continues ... space. Today,s pre-market research on ActiveWallSt.com directs the investor community,s ... RDUS ), Cerus Corp. (NASDAQ: CERS ... Five Prime Therapeutics Inc. (NASDAQ: FPRX ). Register ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... FireflySci cuvettes are used in leading laboratories all over the globe. Their cute ... In addition to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle Plating ... options designed to address fractures of the distal tibia and fibula. This system ... Ankle Plating System 3 is composed of seven plate families that span the ...
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the variety ... that could lead to one good one. Surviving Mesothelioma has just posted an article ... team evaluated 98 mesothelioma patients who got a second kind of drug ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):